文献速递神经肿瘤小儿神经外科与脑积水

利柏西利用于新诊断儿童弥漫内生型桥脑胶质瘤放疗后的I/II期研究

A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
PubMed 文献 · J Neurooncol · 2020-10-09

该I/II期研究评估CDK4/6抑制剂利柏西利在放疗后用于新诊断DIPG患者的安全性、可行性和早期疗效。10例可评估患者(9例DIPG,1例DMG)接受利柏西利(350 mg/m2,28天周期,服21天停7天)。DIPG患者1年总生存率89%,中位OS为16.1个月;常见3/4级毒性为骨髓抑制,4例治疗后MRI显示坏死体积增加。结论认为该方案可行,坏死增加可能代表治疗效应。

要点

  • 利柏西利放疗后给药在儿童DIPG/DMG中可行,中位完成8个周期。
  • DIPG患者1年OS为89%,中位OS为16.1个月。
  • 常见3/4级毒性为骨髓抑制,3例因4级中性粒细胞减少减量。

核心结论

  • 放疗后给予利柏西利在DIPG和DMG中可行,肿瘤坏死增加可能代表治疗效应。

研究设计与样本

  • I/II期研究,纳入10例可评估患者(9例DIPG,1例DMG),年龄3.7至19.8岁。
  • 放疗后接受利柏西利350 mg/m2,28天周期,服21天停7天。
  • 可行性终点包括至少完成6个周期及1次减量后重启治疗延迟小于2周。

主要发现

  • 中位治疗周期数为8(范围3-14)。
  • 3例因4级中性粒细胞减少需减量,1例在第4周期后因血液学毒性停药。
  • 最常见3/4级毒性为骨髓抑制。
  • 2周期后4例MRI显示坏死体积增加,其中3例出现新神经系统症状。
  • DIPG患者1年OS为89%,中位OS为16.1个月(范围10-30);DMG患者诊断后6个月死亡。

关键数值与推荐

  • 利柏西利剂量为350 mg/m2,28天周期中服21天停7天。
  • 可行性定义为至少完成6个周期,且1次减量后重启治疗延迟小于2周。
  • 5例捐献脑组织和肿瘤,其中3例RB阳性。

临床怎么用

  • 利柏西利放疗后方案在儿童DIPG/DMG中可行,但需监测骨髓抑制。
  • 治疗后坏死体积增加需结合临床症状评估,可能代表治疗效应。

局限性

  • 样本量小(10例可评估),仅1例DMG。
  • 坏死体积增加与治疗效应的关联需进一步前瞻性体积分析验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cyclin-dependent kinase-retinoblastoma (CDK-RB) pathway is dysregulated in some diffuse intrinsic pontine gliomas (DIPG). We evaluated safety, feasibility, and early efficacy of the CDK4/6-inhibitor ribociclib, administered following radiotherapy in newly-diagnosed DIPG patients. METHODS: Following radiotherapy, eligible patients received ribociclib in 28-day cycles (350 mg/m2; 21 days on/7 days off). Feasibility endpoints included tolerability for at least 6 courses, and a less than 2-week delay in restarting therapy after 1 dose reduction. Early efficacy was measured by 1-year and median overall survival (OS). Patient/parent-by-proxy reported outcomes measurement information system (PROMIS) assessments were completed prospectively. RESULTS: The study included 10 evaluable patients, 9 DIPG and 1 diffuse midline glioma (DMG)-all 3.7 to 19.8 years of age. The median number of courses was 8 (range 3-14). Three patients required dose reduction for grade-4 neutropenia, and 1 discontinued therapy for hematological toxicity following course 4. The most common grade-3/4 toxicity was myelosuppression. After 2 courses, MRI evaluations in 4 patients revealed increased necrotic volume, associated with new neurological symptoms in 3 patients. The 1-year and median OS for DIPG was 89% and 16.1 months (range 10-30), respectively; the DMG patient died at 6 months post-diagnosis. Five patients donated brain tissue and tumor; 3 were RB+ . CONCLUSIONS: Ribociclib administered following radiotherapy is feasible in DIPG and DMG. Increased tumor necrosis may represent a treatment effect. These data warrant further prospective volumetric analyses of tumors with necrosis. Feasibility and stabilization findings support further investigation of ribociclib in combination therapies. TRIAL REGISTRATION: NCT02607124.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. DeWire M, Fuller C, Hummel TR, et al. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). J Neurooncol. 2020. PMID: 33034839. doi:10.1007/s11060-020-03641-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。